The role of PAR1 autoantibodies in patients with primary epithelial ovarian cancer

Tools

Item Type:	Article
Title:	The role of PAR1 autoantibodies in patients with primary epithelial ovarian cancer
Creators Name:	Kreienbring, K., Franz, A., Richter, R., Dragun, D., Heidecke, H., Müller, D., Mentze, M., Dechend, R., Sehouli, J. and Braicu, E.I.
Abstract:	AIM: This study aimed to analyze the predictive, prognostic and diagnostic value of autoantibodies to coagulation factor II thrombin receptor (F2R; protease-activated receptor 1, PAR1) (PAR1-AB) in patients with primary epithelial ovarian cancer (EOC). MATERIALS AND METHODS: A total of 197 patients with primary EOC and 200 healthy female blood donors were included in the study. Enzyme-linked immunosorbent assay was applied to determine PAR1-AB levels in blood sera taken preoperatively. Correlation of PAR1-AB with clinicopathological outcome, progression-free (PFS) and overall (OS) survival was analyzed and patients were compared with controls. RESULTS: PAR1-AB was significantly negatively correlated with histological grading (p=0.008) and was significantly lower in the patient group compared to healthy controls (p<0.001). There was no significant correlation of PAR1-AB level with PFS or OS. CONCLUSION: This study showed PAR1-AB to significantly decrease in patients with primary EOC and with histological high-grade carcinoma. The relevance of PAR1-AB in early detection of ovarian cancer and follow-up for EOC should be further investigated.
Keywords:	Ovarian Cancer, Diagnostic, Epithelial Neoplasm, Protease Activated Receptor 1, Factor II Thrombin Receptor, Clinicaopathological Outcome, Metalloproteinases
Source:	Anticancer Research
ISSN:	0250-7005
Publisher:	International Institute of Anticancer Research
Volume:	38
Number:	6
Page Range:	3619-3625
Date:	June 2018
Official Publication:	https://doi.org/10.21873/anticanres.12636
PubMed:	View item in PubMed

Repository Staff Only: item control page